Meta-Analysis
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Jan 27, 2024; 16(1): 228-238
Published online Jan 27, 2024. doi: 10.4240/wjgs.v16.i1.228
Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis
Yue Yang, Kan-Zuo Fu, Gu Pan
Yue Yang, Gu Pan, Department of Gastroenterology III, Heilongjiang Provincial Hospital, Harbin 150036, Heilongjiang Province, China
Kan-Zuo Fu, Department of Nursing, The Second Hospital of Harbin, Harbin 150056, Heilongjiang Province, China
Co-first authors: Yue Yang and Kan-Zuo Fu.
Author contributions: Yang Y and Fu KZ wrote the manuscript; Yang Y, Fu KZ, and Pan G collected and analyzed the data; all authors read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gu Pan, BSc, Nurse, Department of Gastroenterology III, Heilongjiang Provincial Hospital, No. 405 Guogoli Street, Nangang District, Harbin 150036, Heilongjiang Province, China. pangu6196@126.com
Received: November 14, 2023
Peer-review started: November 14, 2023
First decision: December 8, 2023
Revised: December 19, 2023
Accepted: December 29, 2023
Article in press: December 29, 2023
Published online: January 27, 2024
Processing time: 71 Days and 23.6 Hours
ARTICLE HIGHLIGHTS
Research background

Oncostatin M (OSM) is a pleiotropic factor that participates in several physiological processes such as hematopoiesis, differentiation, regeneration, and inflammation, and pathological processes such as arthritis, ossification, dermatitis, fibrosis, gingivitis, and carcinogenesis.

Research motivation

Higher OSM levels in patients with inflammatory bowel disease (IBD) provided impetus for reviewing the outcomes of studies that evaluated the prognostic role of OSM in IBD patients.

Research objectives

The objective of this research was to systematically review relevant studies and perform meta-analyses of statistical indices for seeking current evidence about the role of OSM in IBD prognosis.

Research methods

After a literature search in electronic databases, studies were identified for synthesis. Meta-analyses were performed to estimate standardized mean differences in OSM levels between responders and non-responders, and to pool correlations of OSM with other inflammatory biomarkers.

Research results

OSM levels were associated with disease severity and were significantly higher in non-responders, in non-remitters, and in patients with no mucosal healing after anti-tumor necrosis factor (anti-TNF) therapy. Area under receiver operator curve values showed considerable variability between studies but in general higher OSM levels were associated with poor prognosis. OSM had significant correlations with Simple Endoscopic Score of Crohn’s disease, Mayo Endoscopic Score, fecal calprotectin, C-reactive protein, and platelet count.

Research conclusions

OSM can potentially determine IBD severity and can predict the outcomes of anti-tumor necrosis factor-based therapies.

Research perspectives

Future studies may refine the outcomes reported herein. It could also be interesting to explore the role of OSM in achieving response to non-anti-TNF therapies.